Phase I Clinical Study of QLS-1304 in the Treatment of Patients With Advanced Malignant Tumors
This study is a multi-center, open label, dose escalation/dose expansion phase I clinical trial aimed at evaluating the safety, tolerability, PK characteristics, and preliminary efficacy characteristics of QLS1304 monotherapy in patients with advanced malignant solid tumors. This study was divided into two stages: dose escalation and dose expansion.
Advanced Malignant Tumor
DRUG: QLS1304 tablet
Dose limited toxicity (DLT) of QLS1304, up to 35 days|Maximum tolerated dose（MTD）of QLS1304, up to 35 days|Recommended Phase II Dose (RP2D) of QLS1304, up to 35 days
adverse event, from the first drug administration to within 30 days for the last treatment dose|Cmax, through study completion, an average of 2 year|objective response rate(ORR), through study completion, assessed up to 24 months|Tmax, through study completion, an average of 2 year|AUC0-t, through study completion, an average of 2 year|AUC0-inf, through study completion, an average of 2 year|CL/F, through study completion, an average of 2 year|Vd/F, through study completion, an average of 2 year|MRT, through study completion, an average of 2 year|t1/2, through study completion, an average of 2 year
This study is a multi-center, open label, dose escalation/dose expansion phase I clinical trial aimed at evaluating the safety, tolerability, PK characteristics, and preliminary efficacy characteristics of QLS1304 monotherapy in patients with advanced malignant solid tumors. This study was divided into two stages: dose escalation and dose expansion.